

Mahrukh A Huseni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1516956/publications.pdf>

Version: 2024-02-01

8
papers

3,233
citations

1163117

8
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

5412
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	30.7	900
2	The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function. <i>Cancer Cell</i> , 2014, 26, 923-937.	16.8	851
3	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	13.7	778
4	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	16.8	262
5	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. <i>Nature Medicine</i> , 2020, 26, 693-698.	30.7	250
6	Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.	12.8	79
7	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	7.1	75
8	CD8+ T cell infiltration in breast and colon cancer: A histologic and statistical analysis. <i>PLoS ONE</i> , 2018, 13, e0190158.	2.5	33